{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T05:28:29Z","timestamp":1734586109312,"version":"3.30.2"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"DOI":"10.1186\/s12936-024-05198-1","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T17:51:55Z","timestamp":1734544315000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating artesunate monotherapy and dihydroartemisinin-piperaquine as potential antimalarial options for prevaccination radical cures during future malaria vaccine field efficacy trials"],"prefix":"10.1186","volume":"23","clinical-trial-number":[{"clinical-trial-number":"nct04601714","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Alphonse","family":"Ou\u00e9draogo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daouda","family":"Ouattara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"San Maurice","family":"Ouattara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amidou","family":"Diarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie S.","family":"Badoum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alimatou","family":"Hema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amidou Z.","family":"Ou\u00e9draogo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Hien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith C.","family":"Bougouma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issa","family":"N\u00e9bi\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9ry","family":"Bocquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Vaillant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred B.","family":"Tiono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sodiomon B.","family":"Sirima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"5198_CR1","volume-title":"World malaria report 2023","author":"WHO","year":"2023","unstructured":"WHO. World malaria report 2023. Geneva: World Health Organization; 2023."},{"key":"5198_CR2","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1111\/j.1469-0691.2011.03612.x","volume":"17","author":"BM Greenwood","year":"2011","unstructured":"Greenwood BM, Targett GA. Malaria vaccines and the new malaria agenda. Clin Microbiol Infect. 2011;17:1600\u20137.","journal-title":"Clin Microbiol Infect"},{"key":"5198_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12936-015-0802-4","volume":"14","author":"P Guyant","year":"2015","unstructured":"Guyant P, Corbel V, Guerin PJ, Lautissier A, Nosten F, Boyer S, et al. Past and new challenges for malaria control and elimination: the role of operational research for innovation in designing interventions. Malar J. 2015;14:279.","journal-title":"Malar J"},{"key":"5198_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(12)60034-8","volume":"379","author":"CJ Murray","year":"2012","unstructured":"Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet. 2012;379:413\u201331.","journal-title":"Lancet"},{"key":"5198_CR5","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/cid\/ciu954","volume":"60","author":"A Ouattara","year":"2015","unstructured":"Ouattara A, Laurens MB. Vaccines against malaria. Clin Infect Dis. 2015;60:930\u20136.","journal-title":"Clin Infect Dis"},{"key":"5198_CR6","unstructured":"Prequalification of Medical Products: Prequalified Vaccines. https:\/\/extranet.who.int\/prequal\/vaccines\/prequalified-vaccines."},{"key":"5198_CR7","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.4049\/jimmunol.179.6.4193","volume":"179","author":"P Bejon","year":"2007","unstructured":"Bejon P, Mwacharo J, Kai O, Todryk S, Keating S, Lowe B, et al. The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by Plasmodium falciparum. J Immunol. 2007;179:4193\u2013201.","journal-title":"J Immunol"},{"key":"5198_CR8","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3390\/pathogens10101277","volume":"10","author":"CL Calle","year":"2021","unstructured":"Calle CL, Mordm\u00fcller B, Singh A. Immunosuppression in malaria: do Plasmodium falciparum parasites hijack the host? Pathogens. 2021;10:1277.","journal-title":"Pathogens"},{"key":"5198_CR9","doi-asserted-by":"crossref","unstructured":"Greenwood BM, Bradley-Moore AM, Bryceson AD, Palit A. Immunosuppression in children with malaria. Lancet. 1972;i:169\u201372.","DOI":"10.1016\/S0140-6736(72)90569-7"},{"key":"5198_CR10","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/infdis\/153.4.763","volume":"153","author":"M Ho","year":"1986","unstructured":"Ho M, Webster HK, Looareesuwan S, Supanaranond W, Phillips RE, Chanthavanich P, et al. Antigen-specific immunosuppression in human malaria due to Plasmodium falciparum. J Infect Dis. 1986;153:763\u201371.","journal-title":"J Infect Dis"},{"key":"5198_CR11","doi-asserted-by":"publisher","first-page":"1058227","DOI":"10.3389\/fimmu.2022.1058227","volume":"13","author":"R Morter","year":"2022","unstructured":"Morter R, Tiono AB, Nebie I, Hague O, Ouedraogo A, Diarra A, et al. Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5\u201317 month-old children in Burkina Faso. Front Immunol. 2022;13:1058227.","journal-title":"Front Immunol"},{"key":"5198_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1586\/erv.10.16","volume":"9","author":"AJ Cunnington","year":"2010","unstructured":"Cunnington AJ, Riley EM. Suppression of vaccine responses by malaria: insignificant or overlooked? Expert Rev Vaccines. 2010;9:409\u201329.","journal-title":"Expert Rev Vaccines"},{"key":"5198_CR13","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.4049\/jimmunol.1202438","volume":"190","author":"J Illingworth","year":"2013","unstructured":"Illingworth J, Butler NS, Roetynck S, Mwacharo J, Pierce SK, Bejon P, et al. Chronic exposure to Plasmodium falciparum is associated with phenotypic evidence of B and T cell exhaustion. J Immunol. 2013;190:1038\u201347.","journal-title":"J Immunol"},{"key":"5198_CR14","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/j.1365-3156.2010.02618.x","volume":"15","author":"A Ouedraogo","year":"2010","unstructured":"Ouedraogo A, Tiono AB, Diarra A, Nebie IO, Konate AT, Sirima SB. The effects of a pre-season treatment with effective antimalarials on subsequent malaria morbidity in under five-year-old children living in high and seasonal malaria transmission area of Burkina Faso. Trop Med Int Health. 2010;15:1315\u201321.","journal-title":"Trop Med Int Health"},{"key":"5198_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1186\/1471-2334-13-535","volume":"13","author":"AB Tiono","year":"2013","unstructured":"Tiono AB, Guelbeogo MW, Sagnon NF, Nebie I, Sirima SB, Mukhopadhyay A, et al. Dynamics of malaria transmission and susceptibility to clinical malaria episodes following treatment of Plasmodium falciparum asymptomatic carriers: results of a cluster-randomized study of community-wide screening and treatment, and a parallel entomology study. BMC Infect Dis. 2013;13:535.","journal-title":"BMC Infect Dis"},{"key":"5198_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005165","volume":"4","author":"C Guinovart","year":"2009","unstructured":"Guinovart C, Aponte JJ, Sacarlal J, Aide P, Leach A, Bassat Q, et al. Insights into long-lasting protection induced by RTS, S\/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children. PLoS ONE. 2009;4: e5165.","journal-title":"PLoS ONE"},{"key":"5198_CR17","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/infdis\/jiv088","volume":"212","author":"K Sonden","year":"2015","unstructured":"Sonden K, Doumbo S, Hammar U, Vafa Homann M, Ongoiba A, Traore B, et al. Asymptomatic multiclonal Plasmodium falciparum infections carried through the dry season predict protection against subsequent clinical malaria. J Infect Dis. 2015;212:608\u201316.","journal-title":"J Infect Dis"},{"key":"5198_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.670775","volume":"12","author":"J Cai","year":"2021","unstructured":"Cai J, Chen S, Zhu F, Lu X, Liu T, Xu W. Whole-killed blood-stage vaccine: is it worthwhile to further develop it to control malaria? Front Microbiol. 2021;12: 670775.","journal-title":"Front Microbiol"},{"key":"5198_CR19","doi-asserted-by":"publisher","first-page":"8198","DOI":"10.1016\/j.vaccine.2007.07.057","volume":"25","author":"P Bejon","year":"2007","unstructured":"Bejon P, Mwangi T, Lowe B, Peshu N, Hill AV, Marsh K. Clearing asymptomatic parasitaemia increases the specificity of the definition of mild febrile malaria. Vaccine. 2007;25:8198\u2013202.","journal-title":"Vaccine"},{"key":"5198_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0010033","volume":"1","author":"VS Moorthy","year":"2004","unstructured":"Moorthy VS, Imoukhuede EB, Milligan P, Bojang K, Keating S, Kaye P, et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA\/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med. 2004;1: e33.","journal-title":"PLoS Med"},{"key":"5198_CR21","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(01)06957-4","volume":"358","author":"KA Bojang","year":"2001","unstructured":"Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, et al. Efficacy of RTS, S\/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet. 2001;358:1927\u201334.","journal-title":"Lancet"},{"key":"5198_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.12688\/wellcomeopenres.15627.1","volume":"5","author":"EN Khaemba","year":"2020","unstructured":"Khaemba EN, Ogwang C, Kinyanjui S, Muindi JM, Koske JK, Kimani D, et al. Comparing drug regimens for clearance of malaria parasites in asymptomatic adults using PCR in Kilifi County, Kenya: an open-label randomised controlled clinical trial (MalPaC). Wellcome Open Res. 2020;5:36.","journal-title":"Wellcome Open Res"},{"key":"5198_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/1475-2875-10-263","volume":"10","author":"CA Morris","year":"2011","unstructured":"Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, Fleckenstein L. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J. 2011;10:263.","journal-title":"Malar J"},{"key":"5198_CR24","volume-title":"Notes on the Design of Bioequivalence Study: Dihydroartemisinin\/Piperaquine Tetraphosphate","author":"WHO","year":"2024","unstructured":"WHO. Notes on the Design of Bioequivalence Study: Dihydroartemisinin\/Piperaquine Tetraphosphate. Geneva: World Health Organization; 2024."},{"key":"5198_CR25","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/QCO.0b013e328332674a","volume":"22","author":"U D'Alessandro","year":"2009","unstructured":"D\u2019Alessandro U. Progress in the development of piperaquine combinations for the treatment of malaria. Curr Opin Infect Dis. 2009;22:588\u201392.","journal-title":"Curr Opin Infect Dis"},{"key":"5198_CR26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0020-7519(98)00217-3","volume":"29","author":"K Raynes","year":"1999","unstructured":"Raynes K. Bisquinoline antimalarials: their role in malaria chemotherapy. Int J Parasitol. 1999;29:367\u201379.","journal-title":"Int J Parasitol"},{"key":"5198_CR27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4269\/ajtmh.2007.77.181","volume":"77","author":"F Nosten","year":"2007","unstructured":"Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg. 2007;77:181\u201392.","journal-title":"Am J Trop Med Hyg"},{"key":"5198_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086936","volume":"9","author":"AB Tiono","year":"2014","unstructured":"Tiono AB, Kangoye DT, Rehman AM, Kargougou DG, Kabore Y, Diarra A, et al. Malaria incidence in children in South-West Burkina Faso: comparison of active and passive case detection methods. PLoS ONE. 2014;9: e86936.","journal-title":"PLoS ONE"},{"key":"5198_CR29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12936-020-03443-x","volume":"19","author":"JB Yaro","year":"2020","unstructured":"Yaro JB, Ouedraogo A, Ouedraogo ZA, Diarra A, Lankouande M, Agboraw E, et al. A cohort study to identify risk factors for Plasmodium falciparum infection in Burkinabe children: implications for other high burden high impact countries. Malar J. 2020;19:371.","journal-title":"Malar J"},{"key":"5198_CR30","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1186\/s12936-021-03926-5","volume":"20","author":"JB Yaro","year":"2021","unstructured":"Yaro JB, Tiono AB, Sanou A, Toe HK, Bradley J, Ouedraogo A, et al. Risk factors associated with house entry of malaria vectors in an area of Burkina Faso with high, persistent malaria transmission and high insecticide resistance. Malar J. 2021;20:397.","journal-title":"Malar J"},{"key":"5198_CR31","unstructured":"WHO ()2012 Policy Recommendation: Seasonal Malaria Chemoprevention (SMC) for Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa. Geneva, World Health Organization"},{"key":"5198_CR32","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1248\/yakushi.127.1709","volume":"127","author":"C Liu","year":"2007","unstructured":"Liu C, Zhang R, Hong X, Huang T, Mi S, Wang N. Pharmacokinetics of piperaquine after single and multiple oral administrations in healthy volunteers. Yakugaku Zasshi. 2007;127:1709\u201314.","journal-title":"Yakugaku Zasshi"},{"key":"5198_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007871","volume":"4","author":"Q Bassat","year":"2009","unstructured":"Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menendez C, et al. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS ONE. 2009;4: e7871.","journal-title":"PLoS ONE"},{"key":"5198_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011880","volume":"5","author":"N Valecha","year":"2010","unstructured":"Valecha N, Phyo AP, Mayxay M, Newton PN, Krudsood S, Keomany S, et al. An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. PLoS ONE. 2010;5: e11880.","journal-title":"PLoS ONE"},{"key":"5198_CR35","volume-title":"Guidelines for malaria","author":"WHO","year":"2023","unstructured":"WHO. Guidelines for malaria. Geneva: World Health Organization; 2023."},{"key":"5198_CR36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0166-6851(93)90077-B","volume":"61","author":"G Snounou","year":"1993","unstructured":"Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, Do Rosario VE, et al. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. Mol Biochem Parasitol. 1993;61:315\u201320.","journal-title":"Mol Biochem Parasitol"},{"key":"5198_CR37","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1093\/jac\/dkab281","volume":"76","author":"M Mairet-Khedim","year":"2021","unstructured":"Mairet-Khedim M, Nsango S, Ngou C, Menard S, Roesch C, Khim N, et al. Efficacy of dihydroartemisinin\/piperaquine in patients with non-complicated Plasmodium falciparum malaria in Yaounde, Cameroon. J Antimicrob Chemother. 2021;76:3037\u201344.","journal-title":"J Antimicrob Chemother"},{"key":"5198_CR38","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.trstmh.2007.05.018","volume":"101","author":"HY Myint","year":"2007","unstructured":"Myint HY, Ashley EA, Day NP, Nosten F, White NJ. Efficacy and safety of dihydroartemisinin-piperaquine. Trans R Soc Trop Med Hyg. 2007;101:858\u201366.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"5198_CR39","doi-asserted-by":"publisher","first-page":"1058660","DOI":"10.3389\/fcimb.2022.1058660","volume":"12","author":"B Abuaku","year":"2022","unstructured":"Abuaku B, Boateng P, Peprah NY, Asamoah A, Duah-Quashie NO, Matrevi SA, et al. Therapeutic efficacy of dihydroartemisinin-piperaquine combination for the treatment of uncomplicated malaria in Ghana. Front Cell Infect Microbiol. 2022;12:1058660.","journal-title":"Front Cell Infect Microbiol"},{"key":"5198_CR40","doi-asserted-by":"crossref","unstructured":"Barradell LB, Fitton A. Artesunate. A review of its pharmacology and therapeutic efficacy in the treatment of malaria. Drugs. 1995;50:714\u201341.","DOI":"10.2165\/00003495-199550040-00009"},{"key":"5198_CR41","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.ijid.2020.03.082","volume":"95","author":"A Kone","year":"2020","unstructured":"Kone A, Sissoko S, Fofana B, Sangare CO, Dembele D, Haidara AS, et al. Different Plasmodium falciparum clearance times in two Malian villages following artesunate monotherapy. Int J Infect Dis. 2020;95:399\u2013405.","journal-title":"Int J Infect Dis"},{"key":"5198_CR42","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s12936-021-03873-1","volume":"20","author":"DG Assefa","year":"2021","unstructured":"Assefa DG, Yismaw G, Makonnen E. Efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria among children in Africa: a systematic review and meta-analysis of randomized control trials. Malar J. 2021;20:340.","journal-title":"Malar J"},{"key":"5198_CR43","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/infdis\/jiy637","volume":"219","author":"A Yeka","year":"2019","unstructured":"Yeka A, Wallender E, Mulebeke R, Kibuuka A, Kigozi R, Bosco A, et al. Comparative efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Ugandan children. J Infect Dis. 2019;219:1112\u201320.","journal-title":"J Infect Dis"},{"key":"5198_CR44","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12936-018-2496-x","volume":"17","author":"S Dama","year":"2018","unstructured":"Dama S, Niangaly H, Djimde M, Sagara I, Guindo CO, Zeguime A, et al. A randomized trial of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. Malar J. 2018;17:347.","journal-title":"Malar J"},{"key":"5198_CR45","unstructured":"Jullien V. Pharmocokinetics of antimalarial drugs. La Lettre de l\u2019Infectiologue; DOSSIER TH\u00c9MATIQUE novembre-d\u00e9cembre 2012, Tome XXVII:239\u2013243."},{"key":"5198_CR46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4269\/ajtmh.2012.12-0058","volume":"87","author":"AW Maiga","year":"2012","unstructured":"Maiga AW, Fofana B, Sagara I, Dembele D, Dara A, Traore OB, et al. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg. 2012;87:23\u20138.","journal-title":"Am J Trop Med Hyg"},{"key":"5198_CR47","doi-asserted-by":"publisher","first-page":"705","DOI":"10.4269\/ajtmh.2005.73.705","volume":"73","author":"NG Schwarz","year":"2005","unstructured":"Schwarz NG, Oyakhirome S, Potschke M, Glaser B, Klein Klouwenberg P, Altun H, et al. 5-day nonobserved artesunate monotherapy for treating uncomplicated Falciparum malaria in young Gabonese children. Am J Trop Med Hyg. 2005;73:705\u20139.","journal-title":"Am J Trop Med Hyg"},{"key":"5198_CR48","volume":"2014","author":"B Zani","year":"2014","unstructured":"Zani B, Gathu M, Donegan S, Olliaro PL, Sinclair D. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2014;2014: CD010927.","journal-title":"Cochrane Database Syst Rev"},{"key":"5198_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023391","volume":"6","author":"AT Konate","year":"2011","unstructured":"Konate AT, Yaro JB, Ouedraogo AZ, Diarra A, Gansane A, Soulama I, et al. Morbidity from malaria in children in the year after they had received intermittent preventive treatment of malaria: a randomised trial. PLoS ONE. 2011;6: e23391.","journal-title":"PLoS ONE"},{"key":"5198_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040242","volume":"4","author":"JJ Aponte","year":"2007","unstructured":"Aponte JJ, Menendez C, Schellenberg D, Kahigwa E, Mshinda H, Vountasou P, et al. Age interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation. PLoS Med. 2007;4: e242.","journal-title":"PLoS Med"},{"key":"5198_CR51","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1086\/314652","volume":"179","author":"A Farnert","year":"1999","unstructured":"Farnert A, Rooth I, Svensson A, Snounou G, Bjorkman A. Complexity of Plasmodium falciparum infections is consistent over time and protects against clinical disease in Tanzanian children. J Infect Dis. 1999;179:989\u201395.","journal-title":"J Infect Dis"},{"key":"5198_CR52","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1128\/CMR.00025-08","volume":"22","author":"DL Doolan","year":"2009","unstructured":"Doolan DL, Dobano C, Baird JK. Acquired immunity to malaria. Clin Microbiol Rev. 2009;22:13\u201336.","journal-title":"Clin Microbiol Rev"},{"key":"5198_CR53","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12936-022-04172-z","volume":"21","author":"F Kirakoya-Samadoulougou","year":"2022","unstructured":"Kirakoya-Samadoulougou F, De Brouwere V, Fokam AF, Ouedraogo M, Ye Y. Assessing the effect of seasonal malaria chemoprevention on malaria burden among children under 5 years in Burkina Faso. Malar J. 2022;21:143.","journal-title":"Malar J"},{"key":"5198_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2021-008021","volume":"7","author":"MA De Cola","year":"2022","unstructured":"De Cola MA, Sawadogo B, Richardson S, Ibinaiye T, Traore A, Compaore CS, et al. Impact of seasonal malaria chemoprevention on prevalence of malaria infection in malaria indicator surveys in Burkina Faso and Nigeria. BMJ Glob Health. 2022;7: e008021.","journal-title":"BMJ Glob Health"},{"key":"5198_CR55","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/s41598-022-05056-7","volume":"12","author":"JB Yaro","year":"2022","unstructured":"Yaro JB, Tiono AB, Ouedraogo A, Lambert B, Ouedraogo ZA, Diarra A, et al. Risk of Plasmodium falciparum infection in south-west Burkina Faso: potential impact of expanding eligibility for seasonal malaria chemoprevention. Sci Rep. 2022;12:1402.","journal-title":"Sci Rep"},{"key":"5198_CR56","doi-asserted-by":"crossref","unstructured":"White NJ, Chotivanich K. Artemisinin-resistant malaria. Clin Microbiol Rev. 2024:e0010924.","DOI":"10.1128\/cmr.00109-24"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-024-05198-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-024-05198-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-024-05198-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T18:05:24Z","timestamp":1734545124000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-024-05198-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5198"],"URL":"https:\/\/doi.org\/10.1186\/s12936-024-05198-1","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"27 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the National Ethics Committee of the Ministry of Health (under deliberation No. 2020-6-101 dated 10\/06\/2020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"377"}}